Sign in or create an account to add this stock to your watchlist.
About Quidel (NASDAQ:QDEL)
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:QDEL
CUSIP74838J10
Phone858-552-1100
Debt
Debt-to-Equity Ratio0.40
Current Ratio1.36
Quick Ratio1.06
Price-To-Earnings
Trailing P/E Ratio101.47
Forward P/E Ratio26.61
P/E Growth1.08
Sales & Book Value
Annual Sales$277.74 million
Price / Sales8.25
Cash Flow$1.0767 per share
Price / Cash56.84
Book Value$8.83 per share
Price / Book6.93
Profitability
EPS (Most Recent Fiscal Year)($0.07)
Net Income$-8,160,000.00
Net Margins3.08%
Return on Equity12.54%
Return on Assets4.75%
Miscellaneous
Employees1,193
Outstanding Shares37,460,000
Quidel (NASDAQ:QDEL) Frequently Asked Questions
What is Quidel's stock symbol?
Quidel trades on the NASDAQ under the ticker symbol "QDEL."
How were Quidel's earnings last quarter?
Quidel Co. (NASDAQ:QDEL) issued its quarterly earnings data on Tuesday, May, 8th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.01 by $0.28. The firm earned $169.10 million during the quarter, compared to the consensus estimate of $151.50 million. Quidel had a return on equity of 12.54% and a net margin of 3.08%. The company's quarterly revenue was up 129.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.45 EPS. View Quidel's Earnings History.
When is Quidel's next earnings date?
What price target have analysts set for QDEL?
8 brokerages have issued twelve-month price objectives for Quidel's stock. Their forecasts range from $47.00 to $65.00. On average, they anticipate Quidel's share price to reach $58.8333 in the next year. View Analyst Ratings for Quidel.
Who are some of Quidel's key competitors?
Some companies that are related to Quidel include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER) and ImmuCell (ICCC).
Who are Quidel's key executives?
Quidel's management team includes the folowing people:
- Mr. Douglas C. Bryant, Pres, CEO & Director (Age 60)
- Mr. Randall J. Steward, CFO & Principal Accounting Officer (Age 64)
- Mr. Robert J. Bujarski, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 50)
- Dr. Werner Kroll, Sr. VP of R&D (Age 61)
- Mr. Edward Keith Russell, Sr. VP of North America Operations (Age 50)
Has Quidel been receiving favorable news coverage?
News articles about QDEL stock have been trending somewhat positive on Saturday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quidel earned a media sentiment score of 0.14 on Accern's scale. They also gave media coverage about the company an impact score of 45.18 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Quidel's major shareholders?
Quidel's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.81%), Millennium Management LLC (2.66%), Dimensional Fund Advisors LP (2.48%), OppenheimerFunds Inc. (2.31%), New York State Common Retirement Fund (2.18%) and Point72 Asset Management L.P. (1.70%). Company insiders that own Quidel stock include Douglas C Bryant, Jack W Schuler, John Tamerius, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel.
Which major investors are selling Quidel stock?
QDEL stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Tamarack Advisers LP, New York State Common Retirement Fund, Mesirow Financial Investment Management Equity Management, Cannell Peter B & Co. Inc., First Light Asset Management LLC, Birchview Capital LP and Legal & General Group Plc. Company insiders that have sold Quidel company stock in the last year include Douglas C Bryant, Jack W Schuler, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Insider Buying and Selling for Quidel.
Which major investors are buying Quidel stock?
QDEL stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Massachusetts Financial Services Co. MA, Eagle Asset Management Inc., OppenheimerFunds Inc., Dimensional Fund Advisors LP, Lisanti Capital Growth LLC and Sei Investments Co.. View Insider Buying and Selling for Quidel.
How do I buy shares of Quidel?
Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quidel's stock price today?
One share of QDEL stock can currently be purchased for approximately $61.20.
How big of a company is Quidel?
Quidel has a market capitalization of $2.32 billion and generates $277.74 million in revenue each year. The company earns $-8,160,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Quidel employs 1,193 workers across the globe.
How can I contact Quidel?
Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected]
MarketBeat Community Rating for Quidel (QDEL)
MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Quidel (NASDAQ:QDEL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Quidel in the last 12 months. Their average twelve-month price target is $58.8333, suggesting that the stock has a possible downside of 3.87%. The high price target for QDEL is $65.00 and the low price target for QDEL is $47.00. There are currently 6 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.25 | 3.25 | 3.00 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
2 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
2 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $58.8333 | $58.50 | $54.20 | $48.50 |
| Price Target Upside: | 3.87% downside | 4.90% upside | 13.84% upside | 24.20% upside |
Quidel (NASDAQ:QDEL) Consensus Price Target History
Quidel (NASDAQ:QDEL) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Quidel (NASDAQ:QDEL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Quidel (NASDAQ QDEL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 89.72%
Quidel (NASDAQ QDEL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/25/2018 | Thomas D Brown | Director | Sell | 30,451 | $61.34 | $1,867,864.34 | 69,960 |  |
| 4/30/2018 | Douglas C Bryant | CEO | Sell | 36,000 | $56.09 | $2,019,240.00 | 306,313 | |
| 4/27/2018 | Douglas C Bryant | CEO | Sell | 12,000 | $56.02 | $672,240.00 | 306,313 | |
| 3/29/2018 | Douglas C Bryant | CEO | Sell | 36,000 | $51.63 | $1,858,680.00 | 306,313 | |
| 3/27/2018 | Douglas C Bryant | CEO | Sell | 12,000 | $51.51 | $618,120.00 | 306,313 | |
| 2/28/2018 | Douglas C Bryant | CEO | Sell | 36,000 | $44.32 | $1,595,520.00 | 302,843 | |
| 2/26/2018 | Douglas C Bryant | CEO | Sell | 12,000 | $44.63 | $535,560.00 | 302,843 | |
| 1/30/2018 | Douglas C Bryant | CEO | Sell | 12,000 | $46.82 | $561,840.00 | 286,493 | |
| 1/22/2018 | Jack W Schuler | Director | Sell | 12,000 | $48.50 | $582,000.00 | | |
| 1/5/2018 | Jack W Schuler | Director | Sell | 4,000 | $47.02 | $188,080.00 | | |
| 1/4/2018 | Ratan S Borkar | SVP | Sell | 29,880 | $45.15 | $1,349,082.00 | 20,253 | |
| 12/29/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $44.10 | $1,587,600.00 | 286,493 | |
| 12/28/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $44.12 | $529,440.00 | 286,493 | |
| 12/27/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $44.50 | $534,000.00 | 286,493 | |
| 12/21/2017 | Jack W Schuler | Director | Sell | 4,000 | $44.60 | $178,400.00 | 3,365,553 | |
| 12/15/2017 | Robert Joseph Bujarski | SVP | Sell | 110,704 | $39.78 | $4,403,805.12 | 79,797 | |
| 12/12/2017 | Randall J Steward | CFO | Sell | 36,383 | $40.09 | $1,458,594.47 | 56,290 | |
| 12/8/2017 | Werner Kroll | SVP | Sell | 16,358 | $40.44 | $661,517.52 | 10,818 | |
| 12/5/2017 | Thomas D Brown | Director | Sell | 12,154 | $39.62 | $481,541.48 | 57,179 | |
| 12/4/2017 | Ratan S Borkar | SVP | Sell | 24,781 | $40.05 | $992,479.05 | 10,811 | |
| 11/30/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $37.36 | $1,344,960.00 | 296,493 | |
| 11/28/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $36.72 | $440,640.00 | 296,493 | |
| 11/9/2017 | Ratan S Borkar | SVP | Sell | 7,965 | $38.91 | $309,918.15 | 11,084 | |
| 11/6/2017 | Werner Kroll | SVP | Sell | 7,565 | $39.50 | $298,817.50 | 10,261 | |
| 10/30/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $41.15 | $493,800.00 | 296,493 | |
| 10/27/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $42.29 | $507,480.00 | 296,493 | |
| 9/29/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $42.91 | $1,544,760.00 | 296,493 | |
| 9/28/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $42.86 | $514,320.00 | 296,493 | |
| 9/27/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $42.17 | $506,040.00 | 296,493 | |
| 8/31/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $34.44 | $1,239,840.00 | 296,493 | |
| 7/31/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $33.83 | $1,217,880.00 | 296,493 | |
| 7/28/2017 | Michael Donald Jr. Abney | SVP | Sell | 1,173 | $33.83 | $39,682.59 | | |
| 7/28/2017 | Randall J Steward | CFO | Sell | 94,215 | $34.09 | $3,211,789.35 | 79,907 | |
| 6/30/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $27.30 | $982,800.00 | 296,493 | |
| 5/31/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $24.98 | $899,280.00 | 296,493 | |
| 5/30/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $25.10 | $301,200.00 | 296,493 | |
| 5/26/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $24.90 | $298,800.00 | 296,493 | |
| 5/2/2017 | Robert Joseph Bujarski | SVP | Sell | 43,225 | $24.27 | $1,049,070.75 | 50,984 | |
| 5/1/2017 | Robert Joseph Bujarski | SVP | Sell | 33,225 | $24.20 | $804,045.00 | 50,984 | |
| 4/28/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $24.16 | $869,760.00 | 296,493 | |
| 3/31/2017 | Douglas C Bryant | CEO | Sell | 37,080 | $22.50 | $834,300.00 | 297,573 | |
| 2/28/2017 | Douglas C. Bryant | CEO | Sell | 106,920 | $21.39 | $2,287,018.80 | | |
| 12/1/2016 | Robert Joseph Bujarski | SVP | Sell | 60,000 | $22.84 | $1,370,400.00 | 74,896 | |
| 11/30/2016 | Douglas C Bryant | CEO | Sell | 72,000 | $22.89 | $1,648,080.00 | 298,011 | |
| 11/29/2016 | Douglas C Bryant | CEO | Sell | 24,000 | $22.84 | $548,160.00 | 298,011 | |
| 11/28/2016 | Douglas C Bryant | CEO | Sell | 24,000 | $23.02 | $552,480.00 | 298,011 | |
| 11/25/2016 | John Tamerius | SVP | Sell | 8,878 | $23.50 | $208,633.00 | 32,418 | |
| 9/30/2016 | Douglas C Bryant | CEO | Sell | 69,168 | $21.76 | $1,505,095.68 | 291,121 | |
| 8/30/2016 | Douglas C Bryant | CEO | Sell | 2,832 | $22.00 | $62,304.00 | 276,843 | |
| 8/9/2016 | Robert Joseph Bujarski | SVP | Sell | 22,057 | $22.58 | $498,047.06 | 60,100 | |
| 8/1/2016 | John Tamerius | SVP | Sell | 7,000 | $23.02 | $161,140.00 | 18,540 | |
| 2/19/2016 | Douglas C. Bryant | CEO | Buy | 3,700 | $13.91 | $51,467.00 | | |
| 12/2/2015 | John Tamerius | SVP | Sell | 21,109 | $21.95 | $463,342.55 | 26,854 | |
| 10/30/2015 | Douglas C Bryant | CEO | Buy | 20,000 | $19.76 | $395,200.00 | 249,404 | |
| 10/3/2014 | John Tamerius | SVP | Sell | 5,000 | $28.00 | $140,000.00 | | |
| 9/18/2014 | John Tamerius | SVP | Sell | 10,000 | $26.50 | $265,000.00 | | |
| 7/24/2014 | Douglas C Bryant | CEO | Buy | 20,000 | $24.12 | $482,400.00 | | |
| 7/23/2014 | John Tamerius | SVP | Sell | 15,000 | $24.50 | $367,500.00 | | |
| 6/24/2014 | John Tamerius | SVP | Sell | 5,000 | $23.06 | $115,300.00 | | |
| 2/26/2014 | John Tamerius | SVP | Sell | 47,246 | $27.69 | $1,308,241.74 | 32,019 | |
| 2/13/2014 | Rodney Dammeyer | Director | Sell | 26,000 | $27.70 | $720,200.00 | | |
| 10/29/2013 | Mark Pulido | Director | Sell | 12,750 | $25.31 | $322,702.50 | | |
| 5/29/2013 | Robert Joseph Bujarski | SVP | Sell | 28,808 | $23.16 | $667,193.28 | | |
| 5/17/2013 | Robert Joseph Bujarski | SVP | Sell | 27,479 | $23.12 | $635,314.48 | | |
(Data available from 1/1/2013 forward)
Quidel (NASDAQ QDEL) News Headlines
| Source: |
|
Quidel (NASDAQ:QDEL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Quidel (NASDAQ:QDEL) Income Statement, Balance Sheet and Cash Flow Statement
Quidel (NASDAQ QDEL) Stock Chart for Saturday, May, 26, 2018
Loading chart…
